Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

BACKGROUND: Risankizumab has demonstrated durable, high rates of efficacy in patients with moderate‐to‐severe plaque psoriasis as assessed by the achievement of relative Psoriasis Area and Severity Index (PASI) improvement and Dermatology Life Quality Index (DLQI) 0/1. OBJECTIVES: The aim of this po...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooderham, M., Pinter, A., Ferris, L.K., Warren, R.B., Zhan, T., Zeng, J., Soliman, A.M., Kaufmann, C., Kaplan, B., Photowala, H., Strober, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314097/
https://www.ncbi.nlm.nih.gov/pubmed/35174556
http://dx.doi.org/10.1111/jdv.18010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314097/
https://www.ncbi.nlm.nih.gov/pubmed/35174556
http://dx.doi.org/10.1111/jdv.18010

Ejemplares similares